Carol Saunders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carol Saunders has a total of 526 co-authors. Here are the top co-authors by number of shared publications:
- Emily G. Farrow
Genomic Medicine Center, Children’s Mercy Kansas City, Kansas City, USA
9 shared publications - Isabelle Thiffault
Department of Pathology and Laboratory Medicine Children's Mercy Kansas City Kansas City Missouri USA
8 shared publications Isabelle Thiffault
Department of Pathology and Laboratory Medicine Children's Mercy Hospital Kansas City Missouri USA
7 shared publications- Neil A. Miller
Center for Pediatric Genomic Medicine, Children's Mercy Hospital, 2420 Pershing Road, Kansas City, MO, 64108, USA
7 shared publications Neil Miller
Genomic Medicine Center, Children’s Mercy Research Institute—Kansas City , 2420 Pershing Rd. Suite 100, Kansas City, MO , USA
7 shared publications- Stephen Francis Kingsmore
Rady Children’s Institute for Genomic Medicine, San Diego, USA
7 shared publications
Latest Publications
- 12 August 2026
- Published by BMJ in Journal of Medical Genetics
- Vol. 63 (11) , 749-754
BHLHE22 monoallelic and biallelic variants cause a neurodevelopmental disorder with agenesis of the corpus callosum, intellectual disability, abnormal muscle tone and movement abnormalities
Background BHLHE22 encodes a basic helix-loop-helix transcription factor expressed exclusively in the retina and central nervous system and functions as an important regulator of neuronal differentiation. However, BHLHE22 has not yet been associated with a Mendelian neurodevelopmental or neurological disorder. Methods 15 individuals from 13 unrelated families carrying BHLHE22 variants identified by exome sequencing were collected through an international collaboration. Results De novo missense variants located in the highly conserved helix-loop-helix domain of the protein were found in six individuals, and one recurrent homozygous frameshift variant, NP_689627.1:p.Gly74AlafsTer18, was found in nine individuals. Frequent clinical features include absent or limited speech (10/13), delayed or impaired motor abilities (11/13), intellectual disability (ID; 9/12), partial or complete agenesis of the corpus callosum (12/15), involuntary movements and/or stereotypies (11/13) and abnormal muscle tone (13/13), depending on data availability. Two individuals developed spastic paraplegia, without ID or callosal anomalies. One individual had moderate developmental delay and ID but without callosal anomalies. Conclusion Collectively, our data establish BHLHE22 as a previously unrecognized neurodevelopmental disease gene. Disruption of BHLHE22, through either dominant or recessive variants, results in a distinct syndrome characterised by abnormalities in brain development, cognition, tone and movement.
- 12 August 2026
- Published by BMJ in Journal of Medical Genetics
- Vol. 63 (11) , 749-754
BHLHE22 monoallelic and biallelic variants cause a neurodevelopmental disorder with agenesis of the corpus callosum, intellectual disability, abnormal muscle tone and movement abnormalities
Background BHLHE22 encodes a basic helix-loop-helix transcription factor expressed exclusively in the retina and central nervous system and functions as an important regulator of neuronal differentiation. However, BHLHE22 has not yet been associated with a Mendelian neurodevelopmental or neurological disorder. Methods 15 individuals from 13 unrelated families carrying BHLHE22 variants identified by exome sequencing were collected through an international collaboration. Results De novo missense variants located in the highly conserved helix-loop-helix domain of the protein were found in six individuals, and one recurrent homozygous frameshift variant, NP_689627.1:p.Gly74AlafsTer18, was found in nine individuals. Frequent clinical features include absent or limited speech (10/13), delayed or impaired motor abilities (11/13), intellectual disability (ID; 9/12), partial or complete agenesis of the corpus callosum (12/15), involuntary movements and/or stereotypies (11/13) and abnormal muscle tone (13/13), depending on data availability. Two individuals developed spastic paraplegia, without ID or callosal anomalies. One individual had moderate developmental delay and ID but without callosal anomalies. Conclusion Collectively, our data establish BHLHE22 as a previously unrecognized neurodevelopmental disease gene. Disruption of BHLHE22, through either dominant or recessive variants, results in a distinct syndrome characterised by abnormalities in brain development, cognition, tone and movement.
- Open Access
- 29 June 2025
- Published by Wiley in Clinical Genetics
- Vol. 109 (1) , 167-175
Expanding the Genetic and Phenotypic Spectrum of POLRMT ‐Related Mitochondrial Disease
Mitochondrial diseases are a complex group of conditions exhibiting significant phenotypic and genetic heterogeneity. Genomic testing is increasingly used as the first step in the diagnostic pathway for mitochondrial diseases. We used next‐generation sequencing followed by bioinformatic data analysis to identify potentially damaging variants in the POLRMT gene (NM_005035.4) in six new affected individuals. Structural protein analysis predicted the detrimental impact of variants on POLRMT protein structure. Patients show extended phenotypic abnormalities often presenting early in life with features including global developmental delay, cognitive impairment, short stature and muscular hypotonia. This study expands the genetic and phenotypic landscape of mitochondrial disease associated with POLRMT variants.
- 29 June 2025
- Published by Wiley in Clinical Genetics
- Vol. 109 (1) , 167-175
Open AccessExpanding the Genetic and Phenotypic Spectrum of POLRMT ‐Related Mitochondrial Disease
Mitochondrial diseases are a complex group of conditions exhibiting significant phenotypic and genetic heterogeneity. Genomic testing is increasingly used as the first step in the diagnostic pathway for mitochondrial diseases. We used next‐generation sequencing followed by bioinformatic data analysis to identify potentially damaging variants in the POLRMT gene (NM_005035.4) in six new affected individuals. Structural protein analysis predicted the detrimental impact of variants on POLRMT protein structure. Patients show extended phenotypic abnormalities often presenting early in life with features including global developmental delay, cognitive impairment, short stature and muscular hypotonia. This study expands the genetic and phenotypic landscape of mitochondrial disease associated with POLRMT variants.
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6721) , 516-525
Brain malformations and seizures by impaired chaperonin function of TRiC
Malformations of the brain are common and vary in severity, from negligible to potentially fatal. Their causes have not been fully elucidated. Here, we report pathogenic variants in the core protein-folding machinery TRiC/CCT in individuals with brain malformations, intellectual disability, and seizures. The chaperonin TRiC is an obligate hetero-oligomer, and we identify variants in seven of its eight subunits, all of which impair function or assembly through different mechanisms. Transcriptome and proteome analyses of patient-derived fibroblasts demonstrate the various consequences of TRiC impairment. The results reveal an unexpected and potentially widespread role for protein folding in the development of the central nervous system and define a disease spectrum of “TRiCopathies.”
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6721) , 516-525
Brain malformations and seizures by impaired chaperonin function of TRiC
Malformations of the brain are common and vary in severity, from negligible to potentially fatal. Their causes have not been fully elucidated. Here, we report pathogenic variants in the core protein-folding machinery TRiC/CCT in individuals with brain malformations, intellectual disability, and seizures. The chaperonin TRiC is an obligate hetero-oligomer, and we identify variants in seven of its eight subunits, all of which impair function or assembly through different mechanisms. Transcriptome and proteome analyses of patient-derived fibroblasts demonstrate the various consequences of TRiC impairment. The results reveal an unexpected and potentially widespread role for protein folding in the development of the central nervous system and define a disease spectrum of “TRiCopathies.”
- Open Access
Basic helix-loop-helix transcription factor BHLHE22 monoallelic and biallelic variants cause a neurodevelopmental disorder with agenesis of the corpus callosum, intellectual disability, tone and movement abnormalities
BHLHE22 encodes a Class II basic helix-loop-helix transcription factor (bHLH). It is expressed exclusively in the retina and central nervous system (CNS), and functions as an important regulator of retinogenesis and neuronal differentiation. Mice lacking bhlhe22 show nearly complete loss of three brain comminsure, including the corpus callosum. Here we report eleven individuals from nine unrelated families with BHLHE22 variants, with a neurodevelopmental disorder presenting with absent or limited speech, severely impaired motor abilities, intellectual disability (ID), involuntary movements, autistic traits with stereotypies, abnormal muscle tone. The majority of individuals have partial or complete agenesis of the corpus callosum (ACC). Additional symptoms comprised of epilepsy, variable dysmorphic features, and eye anomalies. One additional individual had spastic paraplegia without delayed development and ACC, expanding the phenotype to milder and later onset forms. Four individuals carry de novo missense variants within the highly conserved helix-loop-helix domain while seven individuals from five unrelated families carry a recurrent homozygous frameshift variant, p.(Gly74Alafs*18). Our findings implicate BHLHE22 variants in causing a previously unidentified autosomal dominant and recessive neurodevelopmental disorder associated with ACC, severe motor, language, and cognitive delays, abnormal tone, and involuntary movements. To our knowledge, this is the first report of Class II bHLH variants in humans shown to significantly disrupt brain development, cognition, and movement.
Open AccessBasic helix-loop-helix transcription factor BHLHE22 monoallelic and biallelic variants cause a neurodevelopmental disorder with agenesis of the corpus callosum, intellectual disability, tone and movement abnormalities
BHLHE22 encodes a Class II basic helix-loop-helix transcription factor (bHLH). It is expressed exclusively in the retina and central nervous system (CNS), and functions as an important regulator of retinogenesis and neuronal differentiation. Mice lacking bhlhe22 show nearly complete loss of three brain comminsure, including the corpus callosum. Here we report eleven individuals from nine unrelated families with BHLHE22 variants, with a neurodevelopmental disorder presenting with absent or limited speech, severely impaired motor abilities, intellectual disability (ID), involuntary movements, autistic traits with stereotypies, abnormal muscle tone. The majority of individuals have partial or complete agenesis of the corpus callosum (ACC). Additional symptoms comprised of epilepsy, variable dysmorphic features, and eye anomalies. One additional individual had spastic paraplegia without delayed development and ACC, expanding the phenotype to milder and later onset forms. Four individuals carry de novo missense variants within the highly conserved helix-loop-helix domain while seven individuals from five unrelated families carry a recurrent homozygous frameshift variant, p.(Gly74Alafs*18). Our findings implicate BHLHE22 variants in causing a previously unidentified autosomal dominant and recessive neurodevelopmental disorder associated with ACC, severe motor, language, and cognitive delays, abnormal tone, and involuntary movements. To our knowledge, this is the first report of Class II bHLH variants in humans shown to significantly disrupt brain development, cognition, and movement.
- 21 September 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (2) , e63886
SF3B2 Haploinsufficiency Associated With Hirschprung Disease and Complex Cardiac Defect Without Craniofacial Microsomia
Haploinsufficiency of SF3B2 is associated with craniofacial microsomia, characterized by mandibular hypoplasia and microtia, often with preauricular tags or pits, epibulbar dermoids, and cleft palate. In addition, extracraniofacial anomalies may be present, such as skeletal, cardiac renal, and abnormalities of the central nervous system. Variants have been either de novo or inherited, and both inter‐ and intrafamilial variability has been observed. Here we describe a patient referred for exome sequencing for a complex congenital heart defect and Hirschsprung disease found by exome sequencing to be heterozygous for a loss of function variant, c.945dup (p.Val316SerfsTer5), in SF3B2. This variant was inherited from a parent with an isolated cardiac defect. Interestingly, neither have the defining craniofacial features or other dysmorphisms. This report further illustrates the degree of phenotypic variability seen in SF3B2‐related disease and expands the spectrum to include Hirschsprung disease.
- 21 September 2024
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (2) , e63886
SF3B2 Haploinsufficiency Associated With Hirschprung Disease and Complex Cardiac Defect Without Craniofacial Microsomia
Haploinsufficiency of SF3B2 is associated with craniofacial microsomia, characterized by mandibular hypoplasia and microtia, often with preauricular tags or pits, epibulbar dermoids, and cleft palate. In addition, extracraniofacial anomalies may be present, such as skeletal, cardiac renal, and abnormalities of the central nervous system. Variants have been either de novo or inherited, and both inter‐ and intrafamilial variability has been observed. Here we describe a patient referred for exome sequencing for a complex congenital heart defect and Hirschsprung disease found by exome sequencing to be heterozygous for a loss of function variant, c.945dup (p.Val316SerfsTer5), in SF3B2. This variant was inherited from a parent with an isolated cardiac defect. Interestingly, neither have the defining craniofacial features or other dysmorphisms. This report further illustrates the degree of phenotypic variability seen in SF3B2‐related disease and expands the spectrum to include Hirschsprung disease.
- Open Access
- 10 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Variants in LRRC7 lead to intellectual disability, autism, aggression and abnormal eating behaviors
Members of the leucine rich repeat (LRR) and PDZ domain (LAP) protein family are essential for animal development and histogenesis. Densin-180, encoded by LRRC7, is the only LAP protein selectively expressed in neurons. Densin-180 is a postsynaptic scaffold at glutamatergic synapses, linking cytoskeletal elements with signalling proteins such as the α-subunit of Ca2+/calmodulin-dependent protein kinase II. We have previously observed an association between high impact variants in LRRC7 and Intellectual Disability; also three individual cases with variants in LRRC7 had been described. We identify here 33 individuals (one of them previously described) with a dominant neurodevelopmental disorder due to heterozygous missense or loss-of-function variants in LRRC7. The clinical spectrum involves intellectual disability, autism, ADHD, aggression and, in several cases, hyperphagia-associated obesity. A PDZ domain variant interferes with synaptic targeting of Densin-180 in primary cultured neurons. Using in vitro systems (two hybrid, BioID, coimmunoprecipitation of tagged proteins from 293T cells) we identified new candidate interaction partners for the LRR domain, including protein phosphatase 1 (PP1), and observed that variants in the LRR reduced binding to these proteins. We conclude that LRRC7 encodes a major determinant of intellectual development and behaviour.
- 10 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessVariants in LRRC7 lead to intellectual disability, autism, aggression and abnormal eating behaviors
Members of the leucine rich repeat (LRR) and PDZ domain (LAP) protein family are essential for animal development and histogenesis. Densin-180, encoded by LRRC7, is the only LAP protein selectively expressed in neurons. Densin-180 is a postsynaptic scaffold at glutamatergic synapses, linking cytoskeletal elements with signalling proteins such as the α-subunit of Ca2+/calmodulin-dependent protein kinase II. We have previously observed an association between high impact variants in LRRC7 and Intellectual Disability; also three individual cases with variants in LRRC7 had been described. We identify here 33 individuals (one of them previously described) with a dominant neurodevelopmental disorder due to heterozygous missense or loss-of-function variants in LRRC7. The clinical spectrum involves intellectual disability, autism, ADHD, aggression and, in several cases, hyperphagia-associated obesity. A PDZ domain variant interferes with synaptic targeting of Densin-180 in primary cultured neurons. Using in vitro systems (two hybrid, BioID, coimmunoprecipitation of tagged proteins from 293T cells) we identified new candidate interaction partners for the LRR domain, including protein phosphatase 1 (PP1), and observed that variants in the LRR reduced binding to these proteins. We conclude that LRRC7 encodes a major determinant of intellectual development and behaviour.
- Open Access
- 22 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy
Developmental and epileptic encephalopathies (DEEs) feature altered brain development, developmental delay and seizures, with seizures exacerbating developmental delay. Here we identify a cohort with biallelic variants in DENND5A, encoding a membrane trafficking protein, and develop animal models with phenotypes like the human syndrome. We demonstrate that DENND5A interacts with Pals1/MUPP1, components of the Crumbs apical polarity complex required for symmetrical division of neural progenitor cells. Human induced pluripotent stem cells lacking DENND5A fail to undergo symmetric cell division with an inherent propensity to differentiate into neurons. These phenotypes result from misalignment of the mitotic spindle in apical neural progenitors. Cells lacking DENND5A orient away from the proliferative apical domain surrounding the ventricles, biasing daughter cells towards a more fate-committed state, ultimately shortening the period of neurogenesis. This study provides a mechanism for DENND5A-related DEE that may be generalizable to other developmental conditions and provides variant-specific clinical information for physicians and families.
- 22 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Open AccessLoss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy
Developmental and epileptic encephalopathies (DEEs) feature altered brain development, developmental delay and seizures, with seizures exacerbating developmental delay. Here we identify a cohort with biallelic variants in DENND5A, encoding a membrane trafficking protein, and develop animal models with phenotypes like the human syndrome. We demonstrate that DENND5A interacts with Pals1/MUPP1, components of the Crumbs apical polarity complex required for symmetrical division of neural progenitor cells. Human induced pluripotent stem cells lacking DENND5A fail to undergo symmetric cell division with an inherent propensity to differentiate into neurons. These phenotypes result from misalignment of the mitotic spindle in apical neural progenitors. Cells lacking DENND5A orient away from the proliferative apical domain surrounding the ventricles, biasing daughter cells towards a more fate-committed state, ultimately shortening the period of neurogenesis. This study provides a mechanism for DENND5A-related DEE that may be generalizable to other developmental conditions and provides variant-specific clinical information for physicians and families.
- Open Access
- 1 August 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (17)
An atypical form of 60S ribosomal subunit in Diamond-Blackfan anemia linked to RPL17 variants
Diamond-Blackfan anemia syndrome (DBA) is a ribosomopathy associated with loss-of-function variants in more than 20 ribosomal protein (RP) genes. Here, we report the genetic, functional, and biochemical dissection of 2 multigenerational pedigrees with variants in RPL17 , a large ribosomal subunit protein–encoding gene. Affected individuals had clinical features and erythroid proliferation defects consistent with DBA. Further, RPL17/uL22 depletion resulted in anemia and micrognathia in zebrafish larvae, and in vivo complementation studies indicated that RPL17 variants were pathogenic. Lymphoblastoid cell lines (LCLs) derived from patients displayed a ribosomal RNA maturation defect reflecting haploinsufficiency of RPL17 . The proteins encoded by RPL17 variants were not incorporated into ribosomes, but 10%–20% of 60S ribosomal subunits contained a short form of 5.8S rRNA (5.8S C ), a species that is marginal in normal cells. These atypical 60S subunits were actively engaged in translation. Ribosome profiling showed changes of the translational profile, but those are similar to LCLs bearing RPS19 variants. These results link an additional RP gene to DBA. They show that ribosomes can be modified substantially by RPL17 haploinsufficiency but support the paradigm that translation alterations in DBA are primarily related to insufficient ribosome production rather than to changes in ribosome structure or composition.
- 1 August 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (17)
Open AccessAn atypical form of 60S ribosomal subunit in Diamond-Blackfan anemia linked to RPL17 variants
Diamond-Blackfan anemia syndrome (DBA) is a ribosomopathy associated with loss-of-function variants in more than 20 ribosomal protein (RP) genes. Here, we report the genetic, functional, and biochemical dissection of 2 multigenerational pedigrees with variants in RPL17 , a large ribosomal subunit protein–encoding gene. Affected individuals had clinical features and erythroid proliferation defects consistent with DBA. Further, RPL17/uL22 depletion resulted in anemia and micrognathia in zebrafish larvae, and in vivo complementation studies indicated that RPL17 variants were pathogenic. Lymphoblastoid cell lines (LCLs) derived from patients displayed a ribosomal RNA maturation defect reflecting haploinsufficiency of RPL17 . The proteins encoded by RPL17 variants were not incorporated into ribosomes, but 10%–20% of 60S ribosomal subunits contained a short form of 5.8S rRNA (5.8S C ), a species that is marginal in normal cells. These atypical 60S subunits were actively engaged in translation. Ribosome profiling showed changes of the translational profile, but those are similar to LCLs bearing RPS19 variants. These results link an additional RP gene to DBA. They show that ribosomes can be modified substantially by RPL17 haploinsufficiency but support the paradigm that translation alterations in DBA are primarily related to insufficient ribosome production rather than to changes in ribosome structure or composition.
- 3 April 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (4) , 577-583
More Than a Decade of Rapid Genomic Sequencing: Where Are We Now?
Since the first proof of concept paper describing rapid genome sequencing (rGS) in 2012, this testing has become a commonly used tool in the evaluation of patients in neonatal intensive care units (NICUs). It is estimated that 26% of neonates in this setting have rare genetic diseases. Given the heterogeneity of rare disease, broad testing is the fastest route to early definitive diagnosis. Genome sequencing (GS) allows for the most comprehensive analysis, identifying diagnostic variants in about 30% of cases. This includes those on a clinician's differential diagnosis as well as those not thought of, which may be for many reasons including human fallibility, incomplete or undifferentiated clinical presentation, or new gene-disease associations and phenotypic expansions. In the acute setting, the overall time to diagnosis is important, and rGS has been shown by multiple studies to result in a decreased time to diagnosis. Studies of rGS have also evaluated the impact of a rapid diagnosis by examining changes in medical management and length of NICU stay. Overwhelmingly, it has been demonstrated that running a faster test produces a faster answer, which is beneficial in some cases. Which patients are the most likely to benefit from rGS is ill-defined: for a small number it is undeniably lifesaving. The implementation of rGS requires a careful balance between the desire for rapid molecular diagnosis and limited laboratory and institutional/financial resources, with many scientific and ethical questions concerning the benefits, harms, and costs of this approach. Other testing modalities, such as lower-cost sequencing panels and exome sequencing, are also used for rapid diagnosis of critically ill infants, and other use cases have emerged, such as newborn screening. Though rGS is a great step forward, there are still technical shortcomings in the use of short-read sequencing, and much of the genome remains uninterpretable. Perspectives on the use of rGS were gathered from a virtual roundtable panel of experts regarding the eligibility, benefits, ethics, goals, and future directions of this testing, largely restricting the discussion to the use of rGS for the purpose of diagnosing infants in the NICU. The panel addressing this Q&A has expertise in clinical genetics, neonatology, ethics, genetic counseling, and genomic sequencing/laboratory operations.
- 3 April 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (4) , 577-583
More Than a Decade of Rapid Genomic Sequencing: Where Are We Now?
Since the first proof of concept paper describing rapid genome sequencing (rGS) in 2012, this testing has become a commonly used tool in the evaluation of patients in neonatal intensive care units (NICUs). It is estimated that 26% of neonates in this setting have rare genetic diseases. Given the heterogeneity of rare disease, broad testing is the fastest route to early definitive diagnosis. Genome sequencing (GS) allows for the most comprehensive analysis, identifying diagnostic variants in about 30% of cases. This includes those on a clinician's differential diagnosis as well as those not thought of, which may be for many reasons including human fallibility, incomplete or undifferentiated clinical presentation, or new gene-disease associations and phenotypic expansions. In the acute setting, the overall time to diagnosis is important, and rGS has been shown by multiple studies to result in a decreased time to diagnosis. Studies of rGS have also evaluated the impact of a rapid diagnosis by examining changes in medical management and length of NICU stay. Overwhelmingly, it has been demonstrated that running a faster test produces a faster answer, which is beneficial in some cases. Which patients are the most likely to benefit from rGS is ill-defined: for a small number it is undeniably lifesaving. The implementation of rGS requires a careful balance between the desire for rapid molecular diagnosis and limited laboratory and institutional/financial resources, with many scientific and ethical questions concerning the benefits, harms, and costs of this approach. Other testing modalities, such as lower-cost sequencing panels and exome sequencing, are also used for rapid diagnosis of critically ill infants, and other use cases have emerged, such as newborn screening. Though rGS is a great step forward, there are still technical shortcomings in the use of short-read sequencing, and much of the genome remains uninterpretable. Perspectives on the use of rGS were gathered from a virtual roundtable panel of experts regarding the eligibility, benefits, ethics, goals, and future directions of this testing, largely restricting the discussion to the use of rGS for the purpose of diagnosing infants in the NICU. The panel addressing this Q&A has expertise in clinical genetics, neonatology, ethics, genetic counseling, and genomic sequencing/laboratory operations.
- 7 April 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 144, 78-79
Pseudo-Dystonia and Marked Intrafamilial Variability in CADM3-Related Disease
- 7 April 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 144, 78-79
Pseudo-Dystonia and Marked Intrafamilial Variability in CADM3-Related Disease